GENBGenerate Biomedicines, Inc.
Who owns GENB
86 institutions reported holding GENB for 2026Q2, together 154% of the company, more than the 56 a quarter earlier.
Institutions reporting a position · as of 2026Q2 · up from 56 the quarter before
- Shares held by institutions
- 100.0M
Shares held by institutions · 154% of the company · long US equity positions only, as reported on Form 13F
- Reported value
- $1.69B
Reported value · at Jun 30, 2026 prices, not today's
- Opened vs closed
- 41 / 13
Opened vs closed · new positions against positions exited in the latest quarter
Details›
- Reporting quarter2026-06-30
- 2026Q2
- Quarters on record
- 2
- New positions
- 41
- Positions exited
- 13
- Added to
- 22
- Reduced
- 10
- Shares sold shortsettled Sep 15, 2026
- 7.2M
- Short interestof shares outstanding
- 11%
- Days to coverat the average daily volume
- 7.2
- Change in the short positionsince the Aug 31, 2026 count
- −3.7%
| Holder | Shares | % of company | Value |
|---|---|---|---|
| Flagship Ventures Management, Inc. | 62.7M | n/a | $1.06B |
| FMR LLC | 5.2M | n/a | $88M |
| Capital World Investors | 4.2M | n/a | $71M |
| BRAIDWELL LP | 3.3M | n/a | $55M |
| PRICE T ROWE ASSOCIATES INC /MD/ | 2.2M | n/a | $36M |
| NORGES BANK | 2.1M | n/a | $35M |
| ARCH Venture Management, LLC | 1.9M | n/a | $33M |
| HarbourVest Partners LLC | 1.7M | n/a | $29M |
| BlackRock Inc. | 1.7M | n/a | $28M |
| VANGUARD GROUP INC | 1.5M | n/a | $25M |
| Settlement | Shares short | Of shares outstanding | Days to cover |
|---|---|---|---|
| Sep 15, 2026 | 7.2M | 11% | 7.2 |
| Aug 31, 2026 | 7.5M | 11% | 3.7 |
| Aug 14, 2026 | 7.3M | 11% | 15.1 |
| Jul 31, 2026 | 7.3M | 11% | 15.3 |
| Jul 15, 2026 | 7.0M | 11% | 9.4 |
| Jun 30, 2026 | 5.9M | 9.1% | 4.0 |
| Jun 15, 2026 | 4.5M | 7.0% | 4.8 |
| May 29, 2026 | 4.1M | 6.3% | 4.8 |
| May 15, 2026 | 3.5M | 5.3% | 8.5 |
| Apr 30, 2026 | 3.2M | 4.9% | 9.7 |
| Apr 15, 2026 | 2.1M | 3.2% | 5.9 |
| Mar 31, 2026 | 1.4M | 2.1% | 3.9 |
SEC Form 13F data sets (DERA bulk files). 13F is quarterly, filed up to 45 days late, and covers long US equity positions only, no shorts, no derivatives, nothing held below the reporting threshold. The short position is FINRA's consolidated count for each twice-monthly settlement date, as a share of shares outstanding.
Biotechnology
The closest names by size in the same industry